In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG

Ann Intern Med. 2020 Jan 21;172(2):JC3. doi: 10.7326/ACPJ202001210-003.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Cardiovascular Diseases*
  • Coronary Artery Bypass
  • Dyslipidemias*
  • Humans

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • alirocumab